VentriPoint Diagnostics (TSXV:VPT) ROCE % : -213.38% (As of Sep. 2023)

View and export this data going back to 2005. Start your Free Trial

What is VentriPoint Diagnostics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. VentriPoint Diagnostics's annualized ROCE % for the quarter that ended in Sep. 2023 was -213.38%.

VentriPoint Diagnostics ROCE % Historical Data

The historical data trend for VentriPoint Diagnostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VentriPoint Diagnostics ROCE % Chart

VentriPoint Diagnostics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-103.99

-72.42

VentriPoint Diagnostics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-93.45	-85.24	-125.58	-137.30	-213.38

VentriPoint Diagnostics ROCE % Calculation

VentriPoint Diagnostics's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-4.845	/	( ( (9.545 - 1.085)	+	(5.977 - 1.056) )	/ 2 )
	=	-4.845	/	( (8.46	+	4.921)	/ 2 )
	=	-4.845	/	6.6905
	=	-72.42 %

VentriPoint Diagnostics's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-4.64	/	( ( (3.886 - 1.166)	+	(2.916 - 1.287) )	/ 2 )
	=	-4.64	/	( ( 2.72	+	1.629 )	/ 2 )
	=	-4.64	/	2.1745
	=	-213.38 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

VentriPoint Diagnostics (TSXV:VPT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

VentriPoint Diagnostics ROCE % Related Terms

Thank you for viewing the detailed overview of VentriPoint Diagnostics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

VentriPoint Diagnostics (TSXV:VPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » VentriPoint Diagnostics Ltd (TSXV:VPT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VPTDF:USA 5V7:Germany

Address

18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4

Website

https://www.ventripoint.com

VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It develops applications for heart diseases and imaging modalities which includes congenital heart disease, left or right heart failure, and normal hearts. It sells its products in Canada and internationally.

Executives

Robert Hodgkinson

Director

VentriPoint Diagnostics (TSXV:VPT) Headlines

No Headlines